Original Antigenic Sin and Respiratory Syncytial Virus Vaccines

被引：11

作者：

Tripp, Ralph A. ^{[1
]}

Power, Ultan F. ^{[2
]}

机构：

[1] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA

[2] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Sch Med Dent & Biomed Sci, Belfast BT9 7BL, Antrim, North Ireland

来源：

VACCINES | 2019年 / 7卷 / 03期

基金：

英国生物技术与生命科学研究理事会;

关键词：

original antigenic sin; OAS; RSV; vaccines; vaccine effectiveness; VE; immunological memory; PULMONARY INFLAMMATORY RESPONSE; COTTON RATS; PROTECTIVE EFFICACY; BBG2NA VACCINE; FUSION PROTEIN; RSV; IMMUNIZATION; DISEASE; CHALLENGE; INFECTION;

D O I：

10.3390/vaccines7030107

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The original antigenic sin (OAS) theory considers the outcome of the first encounter with an antigen. It favors a memory response to the original antigen upon exposure to a similar or related antigen, and includes both positive and negative impacts of past exposure on the memory response to challenge, and, in particular, on vaccine efficacy. This phenomenon is closely linked with imprinting and the hierarchical nature of immune responses to previously encountered antigens. The focus of this commentary centers on the potential role of OAS or immunological imprinting on respiratory syncytial virus memory responses.

引用

页数：6

共 47 条

[1] Advances in Vaccines to Prevent Viral Respiratory Illnesses in Children [J].

Anderson, Aleisha J. ;

Snelling, Tom L. ;

Moore, Hannah C. ;

Blyth, Christopher C. .

PEDIATRIC DRUGS, 2017, 19 (06) :523-531

[2] Strategic priorities for respiratory syncytial virus (RSV) vaccine development [J].

Anderson, L. J. ;

Dormitzer, P. R. ;

Nokes, D. J. ;

Rappuoli, R. ;

Roca, A. ;

Graham, B. S. .

VACCINE, 2013, 31 :B209-B215

[3] Respiratory syncytial virus vaccine development [J].

Anderson, Larry J. .

SEMINARS IN IMMUNOLOGY, 2013, 25 (02) :160-171

[4] Respiratory syncytial virus entry and how to block it [J].

Battles, Michael B. ;

McLellan, Jason S. .

NATURE REVIEWS MICROBIOLOGY, 2019, 17 (04) :233-245

[5] Repeated annual influenza vaccination and vaccine effectiveness: review of evidence [J].

Belongia, Edward A. ;

Skowronski, Danuta M. ;

McLean, Huong Q. ;

Chambers, Catharine ;

Sundaram, Maria E. ;

De Serres, Gaston .

EXPERT REVIEW OF VACCINES, 2017, 16 (07) :723-736

[6] The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease [J].

Boukhvalova, Marina S. ;

Prince, Gregory A. ;

Soroush, Layla ;

Harrigan, Dolores C. ;

Vogel, Stefanie N. ;

Blanco, Jorge C. G. .

VACCINE, 2006, 24 (23) :5027-5035

[7] Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials [J].

Broadbent, Lindsay ;

Groves, Helen ;

Shields, Michael D. ;

Power, Ultan F. .

INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2015, 9 (04) :169-178

[8] Palivizumab Prophylaxis for Healthy Preterm Infants: More Data Supporting American Academy of Pediatrics Guidelines [J].

Byington, Carrie L. ;

Munoz, Flor M. .

PEDIATRICS, 2016, 138 (02)

[9] Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease [J].

Castilow, Elaine M. ;

Olson, Matthew R. ;

Varga, Steven M. .

IMMUNOLOGIC RESEARCH, 2007, 39 (1-3) :225-239

[10] Inferior immunogenicity and efficacy of respiratory syncytial virus fusion proteinbased subunit vaccine candidates in aged versus young mice [J].

Cayatte, Corinne ;

Bennett, Angie Snell ;

Rajani, Gaurav Manohar ;

Hostetler, Leigh ;

Maynard, Sean K. ;

Lazzaro, Michelle ;

McTamney, Patrick ;

Ren, Kuishu ;

O'Day, Terrence ;

McCarthy, Michael P. ;

Schneider-Ohrum, Kirsten .

PLOS ONE, 2017, 12 (11)

← 1 2 3 4 5 →